A significant increase in Lichen Planus cases has been observed post-COVID-19, with stress, weak immunity, and autoimmune ...

Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse ...

A biotech company is turning heads so far during Tuesday’s session after it shared topline analysis of its Phase 2a ...

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a ...

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics ...

Lipella Pharma receives US FDA nod for expanded access programme for LP-310, an oral rinse formulation to treat oral lichen planus: Pittsburgh Saturday, February 8, 2025, 09:00 Hr ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies ...

Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...

PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...

The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...